Bayer’s Stock Clears a Key Hurdle as a Packed Court Calendar and Trade Probe Take Centre Stage

Bayer shares break above 50-day moving average on 2.13% gain, but focus remains on U.S. Supreme Court preemption decision in Durnell case and new trade investigation.

Bayer’s newly minted AI-powered plant in Leverkusen snapped up a “Facility of the Year Award” from the International Society for Pharmaceutical Engineering last month — a bright spot for a company whose share price has been largely dictated by courtroom drama. Yet while the SOLIDA-1 facility, built between 2019 and 2024, relies on machine learning to continuously refine production processes, the market’s attention is fixed on a very different kind of judgment: the U.S. Supreme Court’s impending ruling in the Durnell case, expected around late June 2026.

The stock provided a technical signal late last week that has buoyed investor sentiment. On Friday, Bayer shares closed at €37.81, a gain of 2.13% on the day, and roughly 5% higher than the previous Friday’s close. Crucially, the price ended the session a hair’s breadth above the 50-day moving average of €37.80 — a short-term bullish trigger that analysts consider a buy signal. Over the past twelve months the equity has rallied about 41% from its August 2025 low of €25.09, though it remains well below the 52-week high of around €50.

The Supreme Court’s decision on whether federal law pre-empts state-law claims over warning labels for glyphosate could fundamentally reshape the thousands of outstanding lawsuits Bayer still faces. Adding to the legal pressure, a planned multibillion-dollar settlement in Missouri is scheduled for a final hearing on July 9. Bayer characterised a recent procedural ruling that sent the settlement back to a lower court as a positive step, but the outcome is far from certain.

Meanwhile, Bayer must also contend with a fresh headwind out of Washington. The U.S. government launched an investigation last Friday into allegedly unfair drug pricing practices in Germany, and Washington has scheduled a September hearing on potential retaliatory tariffs tied to German healthcare reforms that would cut spending on innovative medicines. The twin threats of trade friction and regulatory scrutiny inject an additional layer of uncertainty into the outlook.

Goldman Sachs has trimmed its exposure, reducing its combined voting rights and instruments stake in Bayer from 5.40% to 4.84% as of June 15. That move contrasts with the views of several sell-side analysts. UBS rates the stock a “buy” with a €52 price target, while Jefferies is more cautious, holding an “hold” rating and a €40 target. The wide divergence reflects the binary nature of the legal risks: a favourable Supreme Court ruling could send the stock decisively above its 50-day line, whereas a negative outcome would likely pull the shares back toward the 200-day moving average at €36.22.

Away from the dockets, Bayer is touting operational improvements at the plant level. The company expects production costs to fall by 8% to 12% at the AI-driven facility, generating an additional gross profit of between €800 million and €1.2 billion over the next five years. The return on capital at SOLIDA-1 already exceeds the industry average.

The next scheduled earnings release — second-quarter figures due on August 4 — will provide a routine snapshot of financial health, but the share price trajectory until then will hinge almost entirely on what happens in courtrooms and trade offices on both sides of the Atlantic.